Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06664775 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery
A Phase 3 study of Hemorrhage, sponsored by Corza Medical.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 116
- Enrollment target
- 9
- Study locations
NCT06664775: Recruiting Phase 3 study of Hemorrhage, sponsored by Corza Medical.
NCT06664775 is a Phase 3 study of Hemorrhage that is actively recruiting participants, run by Corza Medical. The registered enrollment target is 116 participants, below the 261-participant average among 20 other Hemorrhage trials with a reported enrollment target (56% lower). The trial reports 9 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06664775, a Phase 3 study of Hemorrhage, is actively recruiting participants, sponsored by Corza Medical.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 116 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this clinical study is to assess the efficacy and safety of TachoSil compared to the widely known and used for \> 60 years local hemostatic product Surgicel Original as an adjunct to control mild to moderate soft tissue bleeding during surgery.
Primary Outcome
Proportion of participants achieving hemostatic success at the target bleeding site (TBS) within 3 minutes after application of study intervention
Conditions Studied
Interventions
- BIOLOGICAL TachoSil
- BIOLOGICAL Surgicel Original
Study Locations (9)
California
- Torrance Memorial - Torrance
Colorado
- St. Anthony Hospital - Lakewood
District of Columbia
- Georgetown University - Washington D.C.
Illinois
- University Of Chicago - Chicago
Indiana
- Indiana University - Indianapolis
Kentucky
- University of Louisville - Louisville
Missouri
- Washington University - St Louis
North Carolina
- Atrium Health Carolinas Medical Center - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2025-04-02 |
| Est. Completion | 2026-06-30 |
| Phase | Phase 3 |
What NCT06664775 shows while recruiting
NCT06664775 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, below the 261-participant average among 20 other Hemorrhage trials with a reported enrollment target (56% lower).
The record links to 1 condition, with Hemorrhage appearing as the primary indexed condition, and to 2 interventions - of which TachoSil is the first listed.
NCT06664775 lists 9 locations in 9 states (California, Colorado, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT06664775 about?
NCT06664775 is a clinical study titled "A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery". The purpose of this clinical study is to assess the efficacy and safety of TachoSil compared to the widely known and used for \> 60 years local hemostatic product Surgicel Original as an adjunct to control mild to moderate soft tissue bleeding during surgery.
What is the current status of trial NCT06664775?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 116 participants. The study started on 2025-04-02. Estimated completion is 2026-06-30.
What conditions does trial NCT06664775 study?
This clinical trial studies the following conditions: Hemorrhage.
What interventions are being tested in trial NCT06664775?
The interventions under investigation include: TachoSil (BIOLOGICAL), Surgicel Original (BIOLOGICAL).
Who is sponsoring clinical trial NCT06664775?
This trial is sponsored by Corza Medical, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06664775 being conducted?
This trial has 9 study locations across California, Colorado, District of Columbia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06664775's enrollment target sits among peer trials
116 12th of 20 higher than 9 of 20 other Hemorrhage trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemorrhage trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TachoSil® Versus Surgicel® Original for the Secondary Treatment of Local Bleeding in Adult and Pediatric Patients Undergoing Hepatic Resection Surgery
COMPLETED · Phase 3
-
Clevidipine in the Treatment of Patients With Acute Hypertension and Intracerebral Hemorrhage (ACCELERATE)
COMPLETED · Phase 3
-
CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial
RECRUITING · Phase 2
-
Changes in Hemorrhage With Prophylactic Oxytocin for Dilation and Evacuation
RECRUITING · Phase 2
-
NIRS Monitoring in Premature Infants
RECRUITING
-
Pharmacogenomics of Warfarin in Hispanics and Latinos
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI